Costco Offers Ozempic and Wegovy at Half Price to Members

Costco has announced a groundbreaking agreement with drug manufacturer Novo Nordisk to provide members access to anti-obesity medications, specifically Ozempic and Wegovy, at approximately half their usual retail price. This initiative allows members with valid prescriptions to purchase a four-week supply of these injectable medications for $499 through Costco’s prescription program. The offer is exclusively available to those paying out of pocket, as many insurance plans do not currently cover these drugs.

Addressing Rising Prices and Demand

The decision to sell these medications comes at a time when prices for GLP-1 drugs have surged due to limited supply. This scarcity has led some individuals to seek out less expensive compounded alternatives, raising concerns that have prompted calls for increased federal oversight. “We want to make sure we offer the real, authentic Wegovy and Ozempic where patients seek care,” stated David Moore, President of Novo Nordisk US, in an interview with NBC News.

Both Ozempic and Wegovy contain semaglutide, an injectable medication designed for managing type 2 diabetes and facilitating weight loss. Semaglutide operates by mimicking the natural hormone known as glucagon-like peptide 1 (GLP-1), which plays a crucial role in appetite regulation and insulin production. By reducing feelings of hunger, semaglutide can result in substantial weight loss for individuals using it.

Public awareness of semaglutide is rapidly increasing. A survey conducted in August indicated that over 80% of Americans were familiar with the medication, with about one-third having tried it or expressing interest in doing so. Novo Nordisk reports that more than 200,000 Wegovy prescriptions are filled weekly in the United States, highlighting the growing demand for these treatments.

Competition and Market Implications

Despite the high demand, Novo Nordisk faces significant competition from pharmacies and clinics offering cheaper, copycat formulations of GLP-1 medications. As of August 2025, nearly 12% of Americans have turned to GLP-1 drugs for weight loss, including around one-fifth of women aged 50 to 64.

Costco’s entry into the GLP-1 market is expected to enhance access for many consumers, particularly given the ongoing challenges with health plans that deny coverage for these medications. By providing a more affordable option, Costco may play a pivotal role in expanding the availability of these weight-loss drugs, further influencing demand in a market increasingly focused on obesity management.